Korro Receives Australian HREC Approval and CTN Clearance to Initiate Phase 1/2a Clinical Study (REWRITE) of KRRO-110 for Alpha-1 Antitrypsin Deficiency

GlobeNewswire11/21 20:30

This TechnipFMC Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

Benzinga11/18 20:54

Korro Bio Initiated at Buy by Jones Trading

Dow Jones11/18 20:31

Korro to Present at the Jefferies London Healthcare Conference

GlobeNewswire11/14 21:00

Korro Bio Shares Are Trading Lower. The Company Reported Q3 Financial Results.

Benzinga11/14 02:24

Korro Bio GAAP EPS of -$2.26

Seeking Alpha11/14 01:24